• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

HUTCHMED (China) Limited - American Depositary Shares (NQ:HCM)

13.75 +0.38 (+2.84%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 39,185
Open 13.52
Bid (Size) 13.64 (100)
Ask (Size) 13.75 (200)
Prev. Close 13.37
Today's Range 13.46 - 14.00
52wk Range 11.51 - 19.50
Shares Outstanding 871,256,270
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
January 06, 2026
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma
January 04, 2026
From HUTCHMED (China) Limited
Via GlobeNewswire

Performance

YTD
+0.7%
+0.7%
1 Month
-2.1%
-2.1%
3 Month
-14.0%
-14.0%
6 Month
-13.7%
-13.7%
1 Year
-13.0%
-13.0%

More News

Read More
News headline image
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification
December 30, 2025
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Earnings Scheduled For August 7, 2025 ↗
August 07, 2025
Via Benzinga
News headline image
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma
December 29, 2025
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors
December 16, 2025
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China
December 07, 2025
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting
November 26, 2025
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
November 05, 2025
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
HUTCHMED Announces Enrollment Completed of SAFFRON Global Phase III Trial of ORPATHYS® and TAGRISSO® Combination for Certain Lung Cancer Patients with MET Overexpression and/or Amplification After Progression on TAGRISSO®
November 04, 2025
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event
November 02, 2025
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
CORRECTION -- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025
October 31, 2025
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025
October 30, 2025
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 22, 2025
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
October 14, 2025
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress
October 13, 2025
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025
October 01, 2025
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
IBEX, Tesla, IonQ, Warner Bros. Discovery And Other Big Stocks Moving Higher On Friday ↗
September 12, 2025
Via Benzinga
News headline image
Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025
September 11, 2025
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025
September 04, 2025
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces Appointment of Acting Chief Executive Officer
August 24, 2025
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China
August 19, 2025
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Reports 2025 Interim Results
August 07, 2025
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED to Announce 2025 Half-Year Financial Results
July 03, 2025
From HUTCHMED (China) Limited
Via GlobeNewswire
News headline image
HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy
June 30, 2025
From HUTCHMED (China) Limited
Via GlobeNewswire

Frequently Asked Questions

Is HUTCHMED (China) Limited - American Depositary Shares publicly traded?
Yes, HUTCHMED (China) Limited - American Depositary Shares is publicly traded.
What exchange does HUTCHMED (China) Limited - American Depositary Shares trade on?
HUTCHMED (China) Limited - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for HUTCHMED (China) Limited - American Depositary Shares?
The ticker symbol for HUTCHMED (China) Limited - American Depositary Shares is HCM on the Nasdaq Stock Market
What is the current price of HUTCHMED (China) Limited - American Depositary Shares?
The current price of HUTCHMED (China) Limited - American Depositary Shares is 13.75
When was HUTCHMED (China) Limited - American Depositary Shares last traded?
The last trade of HUTCHMED (China) Limited - American Depositary Shares was at 01/06/26 04:00 PM ET
What is the market capitalization of HUTCHMED (China) Limited - American Depositary Shares?
The market capitalization of HUTCHMED (China) Limited - American Depositary Shares is 11.98B
How many shares of HUTCHMED (China) Limited - American Depositary Shares are outstanding?
HUTCHMED (China) Limited - American Depositary Shares has 12B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap